Eli Lilly Shares Tumble After Rival Novo?Nordisk Strikes Major Weight Loss Deal

Nauman khan

Wed, May 14, 2025, 2:20 PM 1 min read

Eli Lilly (NYSE:LLY) shares slid much than 3% connected Wednesday aft reports emerged that Novo Nordisk (NYSE:NVO) has struck a licensing woody with Septerna (NASDAQ:SEPN) to co-develop obesity, Type 2 diabetes, and metabolic therapies.

Under the agreement, Novo Nordisk could wage Septerna up to $2.2 cardinal successful milestones, bolstering its pipeline beyond the high-selling Wegovy injectable. Wegovy generated much than $8 cardinal successful 2024 but faces increasing contention arsenic investors oculus a $150 cardinal obesity market.

Novo Nordisk already secured U.S. regulators' acceptance of an oral Wegovy submission, perchance the archetypal pill for obesity. Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting some firms to contention toward much convenient weight?loss pills.

Investors volition ticker upcoming proceedings readouts and regulatory decisions closely. As Novo Nordisk and Eli Lilly vie for obesity leadership, each licensing determination and objective milestone is apt to sway marketplace sentiment.

This nonfiction archetypal appeared connected GuruFocus.